Commentary on Sawangjit et al. (2017): there is still much to be determined before policy makers can choose pharmacy needle and syringe programmes (NSP) confidently over other models of NSP provision

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)248-249
Number of pages2
JournalAddiction
Volume112
Issue number2
DOIs
Publication statusPublished - 1 Feb 2017

Keywords

  • Blood borne viruses
  • coverage
  • injecting risk
  • needle and syringe programme
  • opiate substitution theraphy
  • pharmacy

Cite this